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Summary (150 words) 
Introduction Extracorporeal membrane carbon dioxide removal (ECCO2R) may have a role 
in treatment of patients with hypercapnic respiratory failure and refractory hypoxaemia 
and/or hypercapnia.  
Methods We report on the use, outcomes and complications in United Kingdom intensive 
care units reporting patients on the Extracorporal Life Support Organisation (ELSO) register. 
Results Of 60 patients, 42 (70%) had primarily hypoxic respiratory failure and 18 (30%) 
primarily hypercapnic respiratory failure.  Use of veno-venous procedures increased 
compared to arterio-venous procedures.  Following ECCO2R, ventilatory and blood gas 
parameters improved at 24 hours.  27 (45%) of patients died before ICU discharge, while 27 
(45%) of patients were discharged alive.  The most common complications related to 
thrombosis or haemorrhage. 
Discussion There is limited use of ECCO2R in UK clinical practice and outcomes reflect 
variability in indications and the technology used. Usage is likely to increase with the 
availability of new, simpler, technology.  Further high quality evidence is needed. 
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Introduction 
Acute respiratory failure is a life-threatening condition where the respiratory system’s 
function of oxygenation and/or elimination of carbon dioxide is inadequate, resulting in 
abnormally low levels of oxygen in the blood (hypoxaemia, i.e. arterial oxygen partial 
pressure [PaO2] <8.00kPa) and/or abnormally high carbon dioxide levels in the blood 
(hypercapnia, i.e. arterial carbon dioxide partial pressure [PaCO2] >6.00kPa). Hypercapnic 
respiratory failure may be associated with mild hypoxaemia as found in exacerbations of 
severe chronic obstructive pulmonary disease (COPD) or with significant hypoxaemia in 
conditions such as acute respiratory distress syndrome (ARDS) resulting from pathology 
including pneumonia, sepsis and chest trauma. Patients are often treated with non-invasive 
ventilation (NIV), which delivers ventilatory support via the patient's upper airway through a 
mask interface. For conditions such as COPD, NIV has been demonstrated to prevent the 
need for mechanical ventilation involving endotracheal intubation, and its complications 
including lung injury [1].  Rescue therapy has traditionally been invasive mechanical 
ventilation: this can be a life saving intervention for acute respiratory failure, but despite 
optimal lung protective ventilation, refractory hypoxaemia and/or hypercapnia may result in 
some patients. There is a small body of literature describing a role for extracorporeal 
membrane carbon dioxide removal (ECCO2R) in this circumstance [2]. Other developing 
roles for ECCO2R include the facilitation of better lung protective ventilation in patients with 
ARDS as an adjunct to mechanical ventilation [3].  
Extracorporeal membrane oxygenation (ECMO) and more recently extracorporeal 
membrane carbon dioxide removal (ECCO2R) are techniques that can provide additional 
and alternative respiratory support for patients using specifically designed membrane gas 
exchangers derived from cardiac bypass technology for extracorporeal blood flow. When 
used for respiratory failure, veno-venous ECMO requires high blood flow rates (3-6L/minute) 
to provide full respiratory support for patients to enable both adequate oxygenation and 
carbon dioxide (CO2) clearance. However when CO2 clearance alone is required, much 
lower blood flows are required. CO2 clearance is determined by multiple factors, including 
the carriage of CO2 in the blood (dissolved, as bicarbonate and as carbamino compounds), 
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the gradient between the venous partial pressure of CO2 and the sweep gas CO2, sweep 
gas flow rate, pH, haemoglobin and the efficiency of the gas exchange membrane. From a 
clinical perspective, CO2 removal will occur and can be manipulated by alteration in the 
sweep gas flow rate, which is analogous to minute ventilation in the native lung [4].  As long 
as a concentration gradient across the membrane is maintained with adequate fresh gas 
flow, ECCO2R may be performed with much lower blood flows which enable limited 
oxygenation but can achieve substantial CO2 clearance.  This supplementary, or partial, CO2 
clearance effectively allows for reduced minute ventilation by the native lungs. It is possible 
that this approach may benefit patients with COPD by avoiding mechanical ventilation and 
allow improved lung protective ventilation in patients with ARDS.   The aim is to supplement 
native pulmonary CO2 clearance, either to allow a reduction in mechanical ventilator settings 
with the intention of limiting ventilator induced lung injury in conditions such as ARDS [3,5] or 
to avoid intubation/facilitate early extubation in patients with conditions such as COPD.  
The circuit of the ECCO2R systems can use either arteriovenous (AV) or veno-venous (VV) 
configuration.  AV-ECCO2R drains blood from the patient’s arterial system through a femoral 
arterial line and returns it to the femoral vein, effectively creating an artificial arteriovenous 
shunt.  Consequently AV-ECCO2R relies upon the patient’s circulation and does not require 
a pump as arterial blood pressure maintains blood flow continuously through the circuit and 
is returned through the vein. VV-ECCO2R uses a dual lumen cannula to access blood and a 
centrifugal pump to drive the blood through the gas exchange membrane and is conceptually 
similar to renal replacement therapy widely used in critical care.   AV-ECCO2R has an 
intrinsic risk of arterial injury which may be avoided using the VV technique. Systemic 
anticoagulation is preferred and recommended but not essential for both AV and VV 
ECCO2R . 
A high quality systematic review [6] on the use of ECCO2R for acute respiratory failure 
secondary to acute respiratory distress syndrome included two randomised control trials 
(RCTs) [7,8]  and 12 observational studies with AV and VV ECCO2R used in seven studies 
each.  Neither RCT showed a significant difference with respect to mortality although in the 
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more recent RCT of low flow VV ECCO2R ventilator free days at 28 and 60 days were 
increased only in the more hypoxaemic subgroup with partial pressure of inspired oxygen 
(PaO2)/fraction of inspired oxygen (FiO2) <20 kPa.  Complication rates ranged from 0-25%, 
the most common complication with AV ECCO2R being lower limb ischaemia secondary to 
arterial cannulation.  Other adverse events included compartment syndrome and one lower 
limb amputation. In VV ECCO2R, clotting within the circuit was the most common 
complication. A further systematic review of the use of ECCO2R in exacerbations of COPD 
included 10 studies at high risk of biased reporting on 87 patients.  In 65 out of 70 patients 
intubation was avoided with the use of ECCO2R. Eight out 11 major complications were 
bleeding episodes with one venous perforation at the catheter site, one pneumothorax and a 
retroperitoneal bleed secondary to iliac artery perforation [9]. 
National Institute for Health and Care Excellence (NICE) guidance [10] recommends that 
ECCO2R should only be used in patients with potentially reversible hypercapnic respiratory 
failure or those being considered for lung transplantation; the procedure should only be 
undertaken with special arrangements for clinical governance, consent and audit or 
research, because the evidence on the safety of ECCO2R showed a number of well-
recognised complications, and evidence on its efficacy was limited in quality and quantity.  
A UK survey of Intensive Care Units (ICUs) was carried out with the support of the Intensive 
Care Society, yielding information on UK clinical practice [11].  Out of 141 ICUs (57% 
response rate), 47 (33%) had used ECCO2R, although many had used it infrequently 
(median 2 patients).  The most common indications were pneumonia and asthma, but 
ECCO2R had also been used for a number of other indications including in patients with 
ARDS from non-respiratory sepsis and trauma, in COPD, as a bridge to lung transplant.  AV- 
ECCO2R was more frequently used but more complications were reported. The use of VV- 
ECCO2R as a newer technology was reported to have increased.  The survey indicated 
ECCO2R uptake in UK ICUs is characterised by sporadic use for a range of indications.  
NICE commissioned the Birmingham and Brunel Consortium External Assessment Centre to 
facilitate clinical data collection by clinicians caring for patients receiving ECCO2R in the UK 
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by working with the Extracorporeal Life Support Organization (ELSO) registry. The collection 
of UK ECCO2R patient data in the ELSO register provides an opportunity to consider 
outcomes including safety in a UK cohort of patients.   
Methods 
Aim 
To report on the use, outcomes and complications of ECCO2R. 
Design 
Observational study of ICU patients undergoing ECCO2R 
Setting 
UK ICUs. 
Recruitment of centres 
The ELSO register dataset was edited to allow the recording of ECCO2R procedures and 
outcomes including procedure related adverse events by ELSO members. ICUs that were 
not already full members of ELSO were identified in 2013 through a survey11 . An associate 
membership category was introduced to enable UK ICUs that were not full members (these 
are centres providing ECMO or cardiac extracorporeal support) to register patients receiving 
ECCO2R.  Hospital Episode Statistics (HES) data, manufacturer data and reported use were 
cross-tabulated to inform the process of contacting centres while recognising that HES data 
had some limitations in that data were available only retrospectively and, although the 
ECCO2R procedure was recorded, relevant procedures may have been misclassified. ICUs 
were contacted a second time via email and if needed were telephoned in the summer of 
2014 when registration and input of patient data were once again encouraged as 
appropriate.  A further round of targeted email and telephone follow-up of centres that may 
have had cases was undertaken at the beginning of 2015.  A request for anonymised data 
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for research purposes was made to ELSO and a final anonymous dataset was produced in 
June 2015. 
The study was carried out under the pre-existing arrangements for clinical governance and 
agreements between contributing centres and the ELSO register. 
Statistical considerations 
The co-primary efficacy and safety outcomes of interest were:  discharged home or 
transferred alive from the hospital offering ECCO2R  and adverse events including procedure 
related complications.  Pre-specified adverse events of interest were lower limb ischaemia 
(including compartment syndrome and amputation), arterial, venous and device thrombus 
formation, plasma leakage, vascular access damage and bleeding complications. 
Other outcomes of interest were pre-ECCO2R blood gases and ventilator settings compared 
with those 24 hour post application. 
AV and VV ECCO2R were predefined subgroups. Although diagnostic information was 
included in the ELSO register, the indication for using ECCO2R was not explicitly stated in the 
ELSO registry.  Therefore based on the limited dataset available and taking into account 
ventilator settings, blood gases and haemodynamics prior to ECCO2R to derive a consensus 
opinion, four independent ICU clinicians  retrospectively assessed if patients primarily received 
ECCO2R to manage hypercapnia or to manage the consequences of hypoxia by enabling lung 
protective ventilation. 
Pre-specified subgroups by indication were Acute Respiratory Distress Syndrome (ARDS), 
asthma and chronic obstructive pulmonary disease (COPD).  The rationale for subgroup 
selection was as follows:  ARDS is the indication most reported; however use of ECCO2R in 
asthma has been reported in the UK; and there are trials registered to evaluate its use in 
severe exacerbations of COPD.  In practice, however, the reported indications did not fit 
easily into unique subgroups or reporting was constrained by group size and therefore these 
subgroups have not been reported below. 
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Given that this was an observational register, no formal sample size calculation was carried 
out prior to data collection.  Statistical analysis is descriptive, with statistical tests having only 
been performed for pre-specified subgroups where data were sufficient.  Tests were 
appropriate to the population distribution of the relevant variables and where appropriate 
exact methods and non-parametric tests were used.   
Ethical approval and consent to participate 
The purpose of the ELSO registry is to provide member institutions data to improve quality of 
care to patients but data may also be requested by members for research purposes.  Data 
are submitted as a limited de-identified dataset.  Given purpose of the register is to collect 
data for quality improvement and anonymous data are collected, individual patient consent 
for data entry into the register is not sought.  Approval for this study using anonymized data 
was obtained from the Science, Technology, Engineering and Mathematics Ethical Review 
Committee of the University of Birmingham (reference ERN_15-0556) prior to the request for 
research data from ELSO. 
Results 
ELSO supplied an anonymised download of data on 60 patients registered as having 
received ECCO2R in UK hospitals on 11.6.2015.  
Patient characteristics and clinical course pre-ECCO2R 
Patient characteristics and pre-ECCO2R support are described in Table 1. 78% of patients 
were specified as having received conventional ventilator support while 2 (3%) patients 
received high frequency oscillatory ventilation with the mode of ventilation not specified for 
the remainder.  The median time from admission to ECCO2R treatment was 96 hours 
(interquartile range 18 to 30 hours, n=58), and the median time from intubation to ECCO2R 
was 48 hours (interquartile range 24 to 202 hours, n=51). 
Of the 42 (70.0%) patients considered to have a primarily hypoxic presentation, 24 (57.1%) 
had pneumonia, 5 patients septic shock, 2 were specified as having acute respiratory failure 
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without further qualification, 2 influenza and 8 other underlying diagnoses.  Of the 18 
patients considered to be primarily hypercapnic, 5 had COPD, 3 pneumonia, 2 
pneumothorax, 2 asthma and 6 other underlying diagnoses.   
Pre-ECCO2R history 
22 patients (36.7%), were not recorded as receiving any specific organ support prior to 
ECCO2R, while 18 had one organ support coded, 7 had 2 and 13 more than 2.  The most 
common organ support recorded was vasopressor/inotropic drugs (Table 1). 
Three patients suffered a cardiac arrest prior to being commenced on ECCO2R.  One had 
asthma requiring manual hand ventilation and was eventually discharged alive. One patient 
had a nutritional/metabolic cardiomyopathy and asthma, another parainfluenza virus 
pneumonia and both subsequently died despite recovery from respiratory failure.  A further 
patient with bronchiectasis had ECCO2R as a bridge to lung transplant also  died despite 
recovery from respiratory failure.  One patient with cerebral oedema also required manual 
hand ventilation. 
ECCO2R treatment and outcomes 
ECCO2R treatment characteristics are described in Table 2 below. Arterio-venous (AV) 
ECCO2R predated veno-venous ECCO2R, with VV-ECCO2R becoming the most prevalent 
once this technology became available (Figure 1).   
Patients receiving VV ECCO2R had relatively fewer hours of ECCO2R. The median duration 
and interquartile range of hours on ECCO2R treatment were 192 (108-324) for AV (n=17) 
and 120 (95-208) for VV (n=38) (Mann-Whitney test not statistically significant). 
Blood flow rate at four and 24 hours was only recorded for three patients receiving AV 
ECCO2R. Where the flow rate unit was recorded in ml/minute, this was converted to 
L/minute except for one patient where the incorrect unit of measurement seemed to have 
been recorded. The median and interquartile range at four hours (n=40) for VV-ECCO2R 
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was 0.47 L/min (0.40 to 1.15) and at 24 hours (n=38) was also 0.47 L/min (0.42 to 1.13) 
(Wilcoxon test not statistically significant). Cannulation is described in Table 3. 
When ventilation parameter settings were compared, taking those during the worst ABG 
values in the six hours prior to ECCO2R and those at the best ABG value at 24 hours 
following application of ECCO2R, all ventilation settings were shown to have been reduced 
(Table 2).  Median PaCO2 was reduced with a concomitant improvement in median pH.   
27/60 (45%) patients were discharged from the hospital alive.  Of the 27/60 (45%) patients 
who died in the course of the procedure, 21  had multi-organ failure, four as having 
diagnosis incompatible with life and two following  family requests.  33 (55%) patients 
survived ECCO2R but a further 6/60 (10%) died prior to discharge from the ECCO2R centre.   
Overall survival to discharge rate of 45%.  13 patients, 48.1% of those discharged alive, 
were discharged home.  9 out of 22 patients receiving AV ECCO2R and 18 out of 38 patients 
receiving VV ECCO2R were discharged alive (p=.907).  20/42 (47.6%) of hypoxic patients 
compared with 13/18 (72.2%) hypercapnic patients survived the procedure (p=0.428) and 
17/42 (40.5%) compared with 10/18 (55.6%) were discharged alive (p=0.141).  Age, hours of 
ECCO2R treatment, time from intubation to ECCO2R, worst PaCO2 in the 6 hours before 
ECCO2R, worst PaO2 in the 6 hours before discharge, worst pH in the 6 hours before 
discharge and time from admission to ECCO2R were not associated with death before 
discharge (Mann Whitney test).  10 women (40.0%) compared with 23 men (65.7%) died 
before discharge (p=0.087). 
19 patients (31.7%) experienced complications (Table 4), with 11 having 1 complication, 2 
having 2, 3 having 3, 2 having 4 and 1 having 7.  15 patients (39.5%) of those receiving VV 
ECCO2R and 4 (23.5%) of those receiving AV ECCO2R had 1 or more complication.  3 
patients receiving AV ECCO2R and 4 receiving VV ECCO2R had cannulation site bleeding. 
Discussion 
This observational study of patients of patients undergoing ECCO2R treatment in the UK 
reported to the ELSO registry displays considerable clinical heterogeneity which may be 
11 
 
reflected in the mixed outcomes at discharge.   While ICUs were actively encouraged to 
register patients, complete population coverage was not achieved, in part reflecting 
unanticipated use of ECCO2R for a single patient in many centres. Findings reflect changes 
in practice over time.  Use of ECCO2R in a veno-venous configuration is increasing in 
respect to arterio-venous, advances in the technology and its perceived relative safety. In 
this series it appears that the procedure is used in some patient groups to manage 
hypercapnia and in others, primarily hypoxic patients, to facilitate lung protective ventilation. 
ECCO2R showed some success in reducing PaCO2 and ventilator settings with the potential 
for lung protection, though only limited evidence of efficacy can be provided by a register 
study.  ECCO2R has been used in a relatively sick patient cohort: only 45% left hospital 
alive. As only a small number of patients received high frequency oscillatory ventilation it 
was not possible to specifically look at this subgroup. 
Complication rates were higher than previously reported in a systematic review5 but 
mechanical complications were relatively infrequent, with cannulation site bleeding being the 
most frequent procedure related adverse event.  Assessment of whether other reported 
complications are procedure related is problematic, given the complexity of the included 
patients’ condition.  Interpretation is difficult, given changing technology and experience:  
ECMO requires larger cannulae and no arterial puncture is required for veno-venous 
ECCO2R.  In contrast to earlier studies, lower limb ischaemia, compartment syndrome and 
amputation were not reported: this may be related to increasing experience and use of veno-
venous technology.  Given the sporadic use of the procedure in many centres and patient 
heterogeneity, further multicentre observational studies to capture procedure related adverse 
events and patient outcome, ideally linked to national audit data, would be of value.  
Survival in this relatively sick cohort is within the range reported for observational studies of 
ECCO2R in ARDS.  There are insufficient patients in the study to confirm a difference in 
outcomes based on hypoxaemia vs hypercapnia though the data might be considered to 
support the conclusion that ECCO2R enables a reduction in mechanical ventilation 
requirement in this group of patients.  Evidence on comparative effectiveness from 
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randomised control trials in well characterised patient cohorts is needed.  Ongoing trials 
such as the National Institute of Health Research Health Technology Assessment funded 
trial of protective ventilation with veno-venous lung assist in patients with acute hypoxic 
respiratory failure (REST trial; ISRCTN31262122) and an ongoing trial in exacerbations of 
COPD (NCT02086084) should inform the effectiveness of ECCO2R.   
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Figure 1:  Mode of ECCO2R by treatment year 
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Table 1:  Patient characteristics and pre-ECCO2R support 
 Median  Interquartile 
range 
Minimum Maximum 
Age (n=60) 58 46-68 24 78 
  
n 
 
% 
  
Male  35 58.3   
Female 25 41.7   
     
White 54 90.0   
Asian 3 5.8   
Black 1 1.7   
Other 2 3.4   
     
Hypoxic  42 70.0   
Hypercapnic 18 30.0   
     
Ventilatory support:     
Conventional 47 78.3   
High frequency 
oscillatory ventilation 
2 3.3   
Unknown 11 18.3   
Vasopressor/inotropic 
drugs 
25 41.7 
Norepinephrine 13 22.8 
Neuromuscular 
blockers 
11 19.3 
Steroids 8 13.3 
Narcotics 5 8.3 
Nitric oxide 2 3.5 
Epinephrine 1 1.8 
Milrinone 1 1.8 
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Table 2:  Ventilator settings, blood gases and haemodynamics pre-ECCO2R and at 24 hours of ECCO2R 
  Worst values in 6 hours pre-
ECCO2R 
Best values at 24 hours of ECCO2R  
 n Medi
-an  
inter-quartile 
range 
min
. 
max. n media
n  
inter-quartile 
range 
min
. 
max. p 
(Wilcoxon
) 
Rate/Hz  37 22 17.0-28.0 4 42 36 18 14-24 8 38 .002 
Mean 
airway 
pressure 
21 16 9-27 5 35 21 15 10-23 5 37 .033 
FiO2 54 .70 .50-.90 .21 1.00 .53 .55 .38-.70 .21 1.00 <.000 
Peak 
inspiratory 
pressure/ 
Amplitude 
49 30 26.0-33.25 18 72 45 24 20-28 8 74 <.000 
Positive 
end-
expiratory 
pressure 
46 8 5.0-12.0 0 20 43 10 5-12 1 20 0.032 
pH  55 7.1 7.1-7.3 6.8 7.6 55 7.4 7.3-7.4 7.2 7.5 <.001 
PaCO2 (kPa)  55 11.4 9.0-14.0 3.9 17.0 55 7.0 6.1-8.0 4.3 11.0 <.001 
PaO2 (kPa) 54 10.5 9.0-13.0 3.6 20.1 55 9.3 8.1-10.7 3.2 17.0 <.004 
PaO2 (kPa) 
/FiO2 
52 .17 .12-.23 .05 .48 52 .17 .14-.24 .05 .57 0.555 
Systolic 
blood 
pressure  
39 110 96 -130 64 207 39 123 110-135 83 168 .043 
Diastolic 
blood 
pressure 
39 57 52-73 42 125 39 60 55-70 40 95 .980 
Mean 
arterial 
pressure 
35 72 67-95 52 141 35 84 73-95 61 122 .301 
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Table 3:  Cannulation 
 n 
Mode:  
AV 22 
Cannulation (where specified):  
Left femoral vein/Left femoral artery 3 
Left femoral vein/Right femoral artery 4 
Right femoral vein/Left femoral artery 14 
Unspecified 1 
VV 38 
Cannulation (where specified):  
Left Internal Jugular Vein 2 
Right Femoral Vein 10 
Right Internal Jugular Vein 10 
Unspecified 16 
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Table 4:  Complications 
 n % of patients 
Mechanical:    
Gas exchange membrane 
failure 
1 1.7 
  Pump malfunction 2 3.3 
  Clots: oxygenator 1 1.7 
  Clots: other 2 3.3 
  Cannula problems 1 1.7s 
 7 11.7 
Haemorrhagic:    
  GI haemorrhage 1 1.7 
  Cannulation site bleeding 7 11.7 
Hemolysis (plasma free Hb 
> 50 mg/dl) 
1 1.7 
  Surgical site bleeding 1 1.7 
 10 16.7 
Neurologic:    
  Seizures: EEG 
determined 
1 1.7 
  CNS haemorrhage by 
US/CT 
1 1.7 
 2 3.3 
Renal:    
  Creatinine 1.5 - 3.0 1 1.7 
  Haemofiltration required 5 8.3 
 6 10.0 
Cardiovascular:    
  Inotropes  4 6.7 
  Cardiac arrhythmia 2 3.3 
 6 10.0 
Other:   
Pneumothorax requiring 
treatment 
1 1.7 
  Culture proven infection 5 8.3 
  pH < 7.20 1 1.7 
  Hyperbilirubinemia (> 2 
direct or > 15 total) 
1 1.7 
Abbreviations: GI gastrointestinal, EEG electroencephalogram, CNS central nervous 
system, US ultrasound, CT computed tomography. 
 
 
 
 
